Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Effect of Growth Hormone in Children With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Growth DisorderGrowth Hormone DisorderGrowth Hormone Deficiency in ChildrenIdiopathic Short Stature
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 173
- Registration Number
- NCT00262249
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures
Phase 2
Completed
- Conditions
- Tibia FracturesBone Fracture
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 407
- Registration Number
- NCT00254514
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations
Phase 3
Completed
- Conditions
- MenopauseMenopausal Vasomotor Symptoms
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 576
- Registration Number
- NCT00184795
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, WAtford, United Kingdom
Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT00184665
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
Phase 3
Terminated
- Conditions
- Acquired Bleeding DisorderTrauma
- Interventions
- Drug: placebo
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 554
- Registration Number
- NCT00184548
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
Phase 3
Completed
- Conditions
- Foetal Growth ProblemSmall for Gestational Age
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT00184691
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT00184678
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 708
- Registration Number
- NCT00184600
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Phase 3
Completed
- Conditions
- Foetal Growth ProblemSmall for Gestational Age
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 98
- Registration Number
- NCT00184717
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
Phase 3
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 112
- Registration Number
- NCT00184743
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath